铁粒幼细胞性贫血 中国就医指南

Sideroblastic anemia (SA) is a heterogeneous group of rare hematologic disorders characterized by defective heme synthesis in erythroblasts, leading to the accumulation of non-heme iron in mitochondrial granules—visible as ringed sideroblasts on Prussian blue-stained bone marrow aspirates. This impairment results in ineffective erythropoiesis, microcytic or normocytic anemia, systemic iron overload, and variable clinical severity. SA is broadly classified into hereditary (congenital) and acquired forms. Hereditary SA most commonly arises from mutations in genes involved in mitochondrial iron-sulfur cluster biogenesis or heme synthesis—such as *ALAS2*, *SLC25A38*, *GLRX5*, *ABCB7*, and *FXN* (in Friedreich ataxia–associated cases). Acquired SA is frequently linked to myelodysplastic syndromes (MDS), particularly refractory anemia with ring sideroblasts (RARS) and MDS–RS–SF (with *SF3B1* mutation), but may also result from chronic alcohol use, copper deficiency, zinc toxicity (e.g., from denture adhesives), certain medications (e.g., isoniazid, chloramphenicol, linezolid), or mitochondrial toxins. Epidemiologically, SA is exceedingly rare: hereditary forms affect fewer than 1 in 1,000,000 individuals globally, while acquired SA accounts for ~5–10% of all MDS cases—translating to an estimated incidence of 0.5–2 per 100,000 adults annually in developed countries. It predominantly affects older adults (median age >70 years) in acquired forms, whereas X-linked *ALAS2*-related SA typically presents in childhood or early adulthood, often with male predominance. Key risk factors include germline genetic predisposition, aging, clonal hematopoiesis, chronic alcoholism, prolonged exposure to mitochondrial toxins, and nutritional deficiencies (copper, vitamin B6). Patients commonly experience fatigue, pallor, dyspnea on exertion, tachycardia, and signs of iron overload—including hepatomegaly, skin hyperpigmentation, diabetes mellitus, and cardiac arrhythmias—especially after repeated transfusions. Quality of life is significantly impaired due to chronic anemia-related debility, transfusion dependency, chelation therapy side effects (e.g., gastrointestinal upset, auditory/ocular toxicity), and psychological burden associated with lifelong monitoring and uncertainty about disease progression. In hereditary forms, some patients respond well to high-dose pyridoxine (vitamin B6), improving hemoglobin and reducing transfusion needs; however, many develop progressive iron overload requiring phlebotomy or chelation. Acquired SA, especially MDS-associated, carries higher risks of leukemic transformation and reduced overall survival. Multidisciplinary management—including hematologic surveillance, iron quantification (serum ferritin, MRI liver iron concentration), cardiac evaluation, and genetic counseling—is essential. Early diagnosis via bone marrow examination with iron staining and molecular testing enables tailored intervention and improves long-term outcomes.

# 铁粒幼细胞性贫血治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

• •适用人群：遗传性轻中度型、获得性（如MDS相关）初治患者，血红蛋白≥80 g/L，无严重铁过载
• •药物治疗：

- 去铁治疗（血清铁蛋白＞1000 μg/L）：去铁酮（口服）或去铁胺（皮下泵注），年均药费 1.8万–6.5万元

• •检验检查费（首次评估）：骨髓穿刺+铁染色+基因检测（SF3B1等）+血清铁代谢全套，合计 2,800–4,200元

二、根治性治疗方案

• •适用人群：年轻（＜50岁）、高危MDS相关型、HLA相合供者可及者
• •异基因造血干细胞移植（allo-HSCT）：

- 移植全程（预处理+住院+支持治疗+嵌合体监测）：32万–58万元（公立三甲医院医保报销后自付约12万–25万元）

三、特殊复杂情况处理

• •耐药性/晚期合并重度铁过载（肝铁浓度＞15 mg/g干重）：联合去铁治疗+肝活检+MRI-T2*定量，年增费用 2.5万–4.0万元
• •合并难治性血细胞减少或进展为AML：按MDS/AML强化疗方案执行，单周期化疗（阿扎胞苷+维奈托克）费用 4.2万–7.6万元

方案快速选择指南

✅ 预算有限（＜2万元/年）：B6试验+规律输血+去铁监测 ✅ 中青年高危患者（可耐受高强度治疗）：优先评估allo-HSCT可行性 ✅ 老年/合并症多者：支持治疗+靶向去铁+定期骨髓动态评估